Menu

Precision Medicine Publications

Panda A, Mehnert JM, Hirshfield KM, Riedlinger G, Damare S, Saunders T, Kane M, Sokol L, Stein MN, Poplin E, Rodriguez-Rodriguez L, Silk AW, Aisner J, Chan N, Malhotra J, Frankel M, Kaufman HL, Ali S, Ross JS, White EP, Bhanot G, Ganesan S. Immune Activation and Benefit From Avelumab in EBV-Positive Gastric Cancer. J Natl Cancer Inst. 2018;110(3):316-20. doi: 10.1093/jnci/djx213.  PubMed PMID: 29155997.

Khiabanian H, Hirshfield KM, Goldfinger M, Bird S, Stein M, Aisner J, Toppmeyer D, Wong S, Chan N, Dhar K, Gheeya J, Vig H, Hadigol M, Pavlick D, Ansari S, Ali S, Xia B, Rodriguez-Rodriguez L, Ganesan S. Inference of Germline Mutational Status and Evaluation of Loss of Heterozygosity in High-Depth, Tumor-Only Sequencing Data. JCO Precision Oncology. 2018(2):1-15. doi: 10.1200/po.17.00148.

Dhami J, Hirshfield KM, Ganesan S, Hellmann M, Rojas V, Amorosa JK, Riedlinger GM, Zhong H, Ali SM, Pavlick D, Elvin JA, Rodriguez-Rodriguez L. Comprehensive genomic profiling aids in treatment of a metastatic endometrial cancer. Cold Spring Harb Mol Case Stud. 2018;4(2) doi: 10.1101/mcs.a002089.  PubMed PMID: 29588307.

Panda A, Betigeri A, Subramanian K, Ross JS, Pavlick DC, Ali S, Markowski P, Silk A, Kaufman HL, Lattime E, Mehnert JM, Sullivan R, Lovly CM, Sosman J, Johnson DB, Bhanot G, Ganesan S. Identifying a Clinically Applicable Mutational Burden Threshold as a Potential Biomarker of Response to Immune Checkpoint Therapy in Solid Tumors. JCO Precision Oncology. 2017(1):1-13. doi: 10.1200/po.17.00146.  PubMed PMID: 10.1200/po.17.00146.

Morgan KM, Riedlinger GM, Rosenfeld J, Ganesan S, and Pine SR. Patient-derived xenograft models of non-small cell lung cancer and their potential utility in personalized medicine. Front Oncol. 2017;7:2. doi: 10.3389/fonc.2017.00002.  PubMed PMID: 28154808;  PMCID: 5243815.

Morgan KM, Fischer BS, Lee FY, Shah JJ, Bertino JR, Rosenfeld J, Singh A, Khiabanian H, and Pine SR. Gamma secretase inhibition by BMS-906024 enhances efficacy of paclitaxel in lung adenocarcinoma. Mol Cancer Ther. 2017;16(12):2759-69. doi: 10.1158/1535-7163.MCT-17-0439.  PubMed PMID: 28978720;  PMCID: 5716926.

Mehnert JM, Monjazeb AM, Beerthuijzen JMT, Collyar D, Rubinstein L, Harris LN. The Challenge for Development of Valuable Immuno-oncology Biomarkers. Clin Cancer Res. 2017;23(17):4970-79. doi: 10.1158/1078-0432.CCR-16-3063.  PubMed PMID: 28864725;  PMCID: 5657536.

Kulkarni A, Al-Hraishawi H, Simhadri S, Hirshfield KM, Chen S, Pine S, Jeyamohan C, Sokol L, Ali S, Teo ML, White E, Rodriguez-Rodriguez L, Mehnert JM, and Ganesan S. BRAF Fusion as a Novel Mechanism of Acquired Resistance to Vemurafenib in BRAFV600E Mutant Melanoma. Clin Cancer Res. 2017;23(18):5631-38. doi: 10.1158/1078-0432.CCR-16-0758.  PubMed PMID: 28539463.

Foran DJ, Chen W, Chu H, Sadimin E, Loh D, Riedlinger G, Goodell LA, Ganesan S, Hirshfield K, Rodriguez L, DiPaola RS. Roadmap to a Comprehensive Clinical Data Warehouse for Precision Medicine Applications in Oncology. Cancer Inform. 2017;16:1176935117694349. doi: 10.1177/1176935117694349.  PubMed PMID: 28469389;  PMCID: 5392017.

Yang XZ, Li XX, Zhang YJ, Rodriguez-Rodriguez L, Xiang MQ, Wang HY, Zheng XF. Rab1 in cell signaling, cancer and other diseases. Oncogene. 2016;35(44):5699-704. doi: 10.1038/onc.2016.81.  PubMed PMID: 27041585;  PMCID: 5396462.

Rojas V, Hirshfield KM, Ganesan S, Rodriguez-Rodriguez L. Molecular Characterization of Epithelial Ovarian Cancer: Implications for Diagnosis and Treatment. Int J Mol Sci. 2016;17(12) doi: 10.3390/ijms17122113.  PubMed PMID: 27983698;  PMCID: 5187913.

Rodriguez-Rodriguez L, Hirshfield KM, Rojas V, DiPaola RS, Gibbon D, Hellmann M, Isani S, Leiser A, Riedlinger GM, Wagreich A, Ali SM, Elvin JA, Miller VA, Ganesan S. Use of comprehensive genomic profiling to direct point-of-care management of patients with gynecologic cancers. Gynecol Oncol. 2016;141(1):2-9. doi: 10.1016/j.ygyno.2016.02.021.  PubMed PMID: 27016222;  PMCID: 5796528.  

Paratala BS, Dolfi SC, Khiabanian H, Rodriguez-Rodriguez L, Ganesan S, Hirshfield KM. Emerging Role of Genomic Rearrangements in Breast Cancer: Applying Knowledge from Other Cancers. Biomark Cancer. 2016;8(Supple 1):1-14. doi: 10.4137/BIC.S34417.  PubMed PMID: 26917980;  PMCID: 4756769.  

Mehnert JM, Panda A, Zhong H, Hirshfield K, Damare S, Lane K, Sokol L, Stein MN, Rodriguez-Rodriquez L, Kaufman HL, Ali S, Ross JS, Pavlick DC, Bhanot G, White EP, DiPaola RS, Lovell A, Cheng J, Ganesan S. Immune activation and response to pembrolizumab in POLE-mutant endometrial cancer. J Clin Invest. 2016;126(6):2334-40. doi: 10.1172/JCI84940.  PubMed PMID: 27159395;  PMCID: 4887167.  

Hirshfield KM, Tolkunov D, Zhong H, Ali SM, Stein MN, Murphy S, Vig H, Vazquez A, Glod J, Moss RA, Belyi V, Chan CS, Chen S, Goodell L, Foran D, Yelensky R, Palma NA, Sun JX, Miller VA, Stephens PJ, Ross JS, Kaufman H, Poplin E, Mehnert J, Tan AR, Bertino JR, Aisner J, DiPaola RS, Rodriguez-Rodriguez L, Ganesan S. Clinical Actionability of Comprehensive Genomic Profiling for Management of Rare or Refractory Cancers. Oncologist. 2016 doi: 10.1634/theoncologist.2016-0049.  PubMed PMID: 27566247;  PMCID: 5189630.

Ganguly B, Dolfi SC, Rodriguez-Rodriguez L, Ganesan S, Hirshfield KM. Role of Biomarkers in the Development of PARP Inhibitors. Biomark Cancer. 2016;8(Suppl 1):15-25. doi: 10.4137/BIC.S36679.  PubMed PMID: 26997874;  PMCID: 4786099.

Xie X, Koh JY, Price S, White E, Mehnert JM. Atg7 Overcomes Senescence and Promotes Growth of BrafV600E-Driven Melanoma. Cancer Discov. 2015;5(4):410-23. doi: 10.1158/2159-8290.CD-14-1473.  PubMed PMID: 25673642;  PMCID: 4390491.

Teh JL, Shah R, La Cava S, Dolfi SC, Mehta MS, Kongara S, Price S, Ganesan S, Reuhl KR, Hirshfield KM, Karantza V, Chen S. Metabotropic glutamate receptor 1 disrupts mammary acinar architecture and initiates malignant transformation of mammary epithelial cells. Breast Cancer Res Treat. 2015;151(1):57-73. doi: 10.1007/s10549-015-3365-8.  PubMed PMID: 25859923;  PMCID: 5193007.

Su H, Shen Y, Xing F, Qi X, Hirshfield KM, Yang L, Foran DJ. Robust automatic breast cancer staging using a combination of functional genomics and image-omics. Conf Proc IEEE Eng Med Biol Soc. 2015;2015:7226-9. doi: 10.1109/EMBC.2015.7320059.  PubMed PMID: 26737959;  PMCID: 4918467.

Stein MN, Hirshfield KM, Zhong H, Singer EA, Ali SM, Ganesan S. Response to crizotinib in a patient with MET-mutant papillary renal cell cancer after progression on tivantinib. Eur Urol. 2015;67(2):353-4. doi: 10.1016/j.eururo.2014.10.012.  PubMed PMID: 25457019;  PMCID: 5500309. 

Joshi S, Tolkunov D, Aviv H, Hakimi AA, Yao M, Hsieh JJ, Ganesan S, Chan CS, White E. The Genomic Landscape of Renal Oncocytoma Identifies a Metabolic Barrier to Tumorigenesis. Cell Rep. 2015;13(9):1895-908. doi: 10.1016/j.celrep.2015.10.059.  PubMed PMID: 26655904;  PMCID: 4779191.

Tereshchenko IV, Zhong H, Chekmareva MA, Kane-Goldsmith N, Santanam U, Petrosky W, Stein MN, Ganesan S, Singer EA, Moore D, Tischfield JA, DiPaola RS. ERG and CHD1 heterogeneity in prostate cancer: use of confocal microscopy in assessment of microscopic foci. Prostate. 2014;74(15):1551-9. doi: 10.1002/pros.22873.  PubMed PMID: 25175909;  PMCID: 4181586.

Strohecker AM, White E. Targeting mitochondrial metabolism by inhibiting autophagy in BRAF-driven cancers. Cancer Discov. 2014;4(7):766-72. doi: 10.1158/2159-8290.CD-14-0196.  PubMed PMID: 24860158;  PMCID: 4090279.

Savla R, Garbuzenko OB, Chen S, Rodriguez-Rodriguez L, Minko T. Tumor-targeted responsive nanoparticle-based systems for magnetic resonance imaging and therapy. Pharm Res. 2014;31(12):3487-502. doi: 10.1007/s11095-014-1436-x.  PubMed PMID: 24919932;  PMCID: 4224753.  

Lozy F, Cai-McRae X, Teplova I, Price S, Reddy A, Bhanot G, Ganesan S, Vazquez A, Karantza V. ERBB2 overexpression suppresses stress-induced autophagy and renders ERBB2-induced mammary tumorigenesis independent of monoallelic Becn1 loss. Autophagy. 2014;10(4):662-76. doi: 10.4161/auto.27867.  PubMed PMID: 24492513;  PMCID: 4091153. 

Laddha SV, Ganesan S, Chan CS, White E. Mutational landscape of the essential autophagy gene BECN1 in human cancers. Mol Cancer Res. 2014;12(4):485-90. doi: 10.1158/1541-7786.MCR-13-0614.  PubMed PMID: 24478461;  PMCID: 3989371.

Hirshfield KM, Ganesan S. Triple-negative breast cancer: molecular subtypes and targeted therapy. Curr Opin Obstet Gynecol. 2014;26(1):34-40. doi: 10.1097/GCO.0000000000000038.  PubMed PMID: 24346128.  

Glod J, Song M, Sharma A, Tyagi R, Rhodes RH, Weissmann DJ, Roychowdhury S, Khan A, Kane MP, Hirshfield K, Ganesan S, DiPaola RS, Rodriguez-Rodriguez L. Next generation sequencing as an aid to diagnosis and treatment of an unusual pediatric brain cancer. J Pers Med. 2014;4(3):402-11. doi: 10.3390/jpm4030402.  PubMed PMID: 25563358;  PMCID: 4263965.  

Dolfi SC, Jager AV, Medina DJ, Haffty BG, Yang JM, Hirshfield KM. Fulvestrant treatment alters MDM2 protein turnover and sensitivity of human breast carcinoma cells to chemotherapeutic drugs. Cancer Lett. 2014;350(1-2):52-60. doi: 10.1016/j.canlet.2014.04.009.  PubMed PMID: 24747123;  PMCID: 5500211.  

Shah V, Taratula O, Garbuzenko OB, Taratula OR, Rodriguez-Rodriguez L, Minko T. Targeted nanomedicine for suppression of CD44 and simultaneous cell death induction in ovarian cancer: an optimal delivery of siRNA and anticancer drug. Clin Cancer Res. 2013;19(22):6193-204. doi: 10.1158/1078-0432.CCR-13-1536.  PubMed PMID: 24036854;  PMCID: 3846837.

Minko T, Rodriguez-Rodriguez L, Pozharov V. Nanotechnology approaches for personalized treatment of multidrug resistant cancers. Adv Drug Deliv Rev. 2013;65(13-14):1880-95. doi: 10.1016/j.addr.2013.09.017.  PubMed PMID: 24120655.

Jaspers JE, Kersbergen A, Boon U, Sol W, van Deemter L, Zander SA, Drost R, Wientjens E, Ji J, Aly A, Doroshow JH, Cranston A, Martin NM, Lau A, O'Connor MJ, Ganesan S, Borst P, Jonkers J, Rottenberg S. Loss of 53BP1 causes PARP inhibitor resistance in Brca1-mutated mouse mammary tumors. Cancer Discov. 2013;3(1):68-81. doi: 10.1158/2159-8290.CD-12-0049.  PubMed PMID: 23103855.

 

 

precision medicine at Rutgers Cancer Institute

 

 

 

ScreenNJ

 

 

Donate Now

 

 

 


 

 

 

 

Proud member of
Big Ten Cancer Research Consortium

 

 

Rutgers Health